1	Genentech	NNP	2	nn
2	Inc.	NNP	3	nsubj
3	said	VBD	0	root
4	the	DT	7	det
5	West	NNP	6	nn
6	German	NNP	7	nn
7	distributor	NN	13	nsubj
8	of	IN	7	prep
9	its	PRP$	11	poss
10	heart	NN	11	nn
11	drug	NN	12	nn
12	TPA	NNP	8	pobj
13	reached	VBD	3	ccomp
14	a	DT	17	det
15	joint	NN	16	nn
16	marketing	NN	17	nn
17	agreement	NN	13	dobj
18	with	IN	13	prep
19	a	DT	20	det
20	subsidiary	NN	18	pobj
21	of	IN	20	prep
22	Hoechst	NNP	23	nn
23	AG	NNP	21	pobj
24	,	,	23	punct
25	which	WDT	26	nsubj
26	makes	VBZ	23	rcmod
27	the	DT	30	det
28	rival	JJ	30	amod
29	anti-clotting	JJ	30	amod
30	agent	NN	31	nn
31	streptokinase	NNP	26	dobj
32	.	.	3	punct

1	The	DT	3	det
2	biotechnology	NN	3	nn
3	concern	NN	4	nsubj
4	said	VBD	0	root
5	the	DT	6	det
6	agreement	NN	29	nsubj
7	between	IN	6	prep
8	its	PRP$	12	poss
9	longtime	NN	12	nn
10	West	NNP	11	nn
11	German	NNP	12	nn
12	distributor	NN	7	pobj
13	,	,	12	punct
14	Boehringer-Ingleheim	NNP	20	poss
15	's	POS	14	possessive
16	Dr.	NNP	18	nn
17	Karl	NNP	18	nn
18	Thomae	NNP	19	nn
19	G.m.b.H.	NNP	20	nn
20	subsidiary	NN	12	appos
21	,	,	12	punct
22	and	CC	12	cc
23	Hoechst	NNP	26	poss
24	's	POS	23	possessive
25	Behringwerke	NNP	26	nn
26	subsidiary	NN	12	conj
27	was	VBD	29	cop
28	an	DT	29	det
29	attempt	NN	4	ccomp
30	to	TO	31	aux
31	expand	VB	29	infmod
32	the	DT	33	det
33	market	NN	31	dobj
34	for	IN	33	prep
35	blood-clot	NN	36	nn
36	drugs	NNS	34	pobj
37	in	IN	36	prep
38	general	NN	37	pobj
39	.	.	4	punct

1	A	DT	3	det
2	Genentech	NNP	3	nn
3	spokeswoman	NN	4	nsubj
4	said	VBD	0	root
5	the	DT	6	det
6	agreement	NN	7	nsubj
7	calls	VBZ	4	ccomp
8	for	IN	11	mark
9	Hoechst	NNP	11	nsubj
10	to	TO	11	aux
11	promote	VB	7	advcl
12	TPA	NNP	11	dobj
13	for	IN	11	prep
14	heart	NN	15	nn
15	patients	NNS	13	pobj
16	and	CC	11	cc
17	streptokinase	NNP	11	conj
18	for	IN	17	prep
19	other	JJ	21	amod
20	clot-reducing	JJ	21	amod
21	purposes	NNS	18	pobj
22	.	.	4	punct


